UNSPSC 51283950: Sulfaproxyline

This classification denotes a sulfonamide anti-infective agent with the molecular formula C16H18N2O4S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier YR841R53VW, chemically known as benzamide, p-isopropoxy-n-sulfanilyl- (8ci) but more generally known as sulfaproxyline, which bears U.S. National Institutes of Health Compound Identifier 67002. The European Medicines Agency schedules Sulfaproxyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10722MIG.

The term SULFAPROXYLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). SULFAPROXYLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(NC(=O)C1CCC(OC(C)C)CC1)C1CCC(N)CC1.

UNSPSC 51283950 Sulfaproxyline, a Commodity code, shows minimal direct activity under its nominal scope; recent state and local solicitations tagged with this code are actually soliciting for naloxone, emergency medical supplies, generic pharmaceuticals, and direct-to-manufacturer prescription programs—none of which align with sulfaproxyline procurement. The mismatch suggests either miscoding of opportunities in the state and local procurement system or that the code itself sees little relevant recent activity in this market segment. Where state and local governments do solicit under related pharmaceutical and medical-supply codes, they are purchasing naloxone and drug deactivation systems for community health and emergency response, generic multi-source pharmaceuticals and OTC products for distribution through state and local facilities and cooperative purchasing organizations, and establishing new direct contracting models with pharmaceutical manufacturers to bypass traditional pharmacy benefit managers and wholesalers.

Issuing bodies include county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). Recent representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), Texas HHS's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), and Minnesota's RFP for generic multi-source pharmaceuticals and OTC products through cooperative purchasing (due March 26, 2026). Activity centers in Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple states. The code shows little actionable current activity under its stated pharmaceutical scope.